Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors
      < Back
    • Investors
    • Investors
    • Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Français  FR     EN  arrow_down
    • English EN
    • Français FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • Brazil
    • Canada
    • United States
    • Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Romania
    • Hungary
    • Slovakia
    • Switzerland
    • Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories

Post navigation

Previous
Next

Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

Attachment

  • 2025 Half-year Financial Report_Ipsen SA

Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

- 31 July 2025 - 1 mins read

Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)

Attachment

  • 2025 Half-year Financial Report_Ipsen SA

Post navigation

Previous
Next

Related Press Releases

18 September 2026

Ipsen appoints Mariette Finet to its Board of Directors
15 September 2026

Correction: IPSEN – Buy-back programme – Art 5 of MAR...
14 September 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
07 September 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
03 September 2026

Ipsen – August 2026 – Monthly information relative to the...
31 August 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
24 August 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
20 August 2026

Ipsen – July 2026 – Monthly information relative to the...
17 August 2026

IPSEN – Buy-back programme – Art 5 of MAR –...
10 August 2026

IPSEN – Buy-back programme – Art 5 of MAR –...

IPN price

€155.90

 €0.10 (0.06%)

  • Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy
  • LinkedIn
  • Instagram
  • Facebook
  • Youtube

© Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

What information or content were you unable to find on the Ipsen website?